Objective To observe the protection of Chaishao Chengqi decoction to the intestinal mucosal barrier in rats with severe acute pancreatitis.Methods 72 SD rats were randomly divided into normal control group,SAP group and Chaishao Chengqi decoction therapeutic group.10%L-arginine was injected into the rats abdominal to establish SAP models. Chaishao Chengqi decoction 1ml.kg-1 was injected into the rats' stomach of therapeutic group and repeated injections were given per 6 hours until the rats were executed. Normal control group and SAP group were given isodose stroke-physiological saline solution. Specimens were get at 6,12,24 and 48h for detections:①Pathological change of pancreas and Ileal mucous membrane;②Apoptotic index of Ileal mucous membrane;③TNF-α contents of blood serum. Results Apoptotic index of Ileal mucous membrane in SAP group was significantly higher than Normal control group and therapeutic group(P＜0.05);TNF-α contents of SAP group was significantly higher than normal control group and theraroup(P＜0.05);Pathological lesion of pancreas and Ileal mucous membrane of therapeutic group was slighter than SAP group.Conclusions Our experiment suggested that excessus apoptosis of intestinal mucosa was one of the main mechanisms of mucosal barrier function disorder in SAP. Chaishao Chengqi decoction has a protective effect on the intestinal mucosal barrier function.

Objective To analyze the relationship between obstructive sleep apnea syndrome (OSAS) and metabolic syndrome (MS) in petrol field workers.Methods A total of 100 cases of OSAS patients of petrol field workers were enrolled as the study objects from March 2013 to August 2015 in emergency and respiratory department in Daqing Longnan Hospital and were divided into three groups:simple snoring group (Group A,n =26),mild OSAS group (Group B,n =42),and severe OSAS group (Group C,n =32).The comparison of dietetic status score,sleep status score and the patients with MS among 3 groups were carried out.The relationship between OSAS and MS was analyzed by using univariate and multivariable Logistic regression analyses were used.Results In Group C,sleep status score (8.3 ± 1.2) and dietetic status score (7.6 ± 1.4) and the rates of MS (23/32) were higher than those in the other two groups (P ＜ 0.05).Univariate and multivariable Logistic regression analyses,showed OSAS was the risk factorofMS [r=11.211 (OR =9.412,95％ CI:5.992～15.202)].Conclusions Dietetic status and sleep status were obviously influenced by OSAS in petrol field workers.The incidence of MS were more common in petrol field workersevere with OSAS and OSAS was a risk factor of MS.

Objective to investigate the curative effect of activated vitamin D3 combined with IFN-α on CCl4-induced hepatic fibrosis in BALB/c mouse model. Methods the experimental mice received 100 μL of 10% CCl4 intraperitoneally to induce a model of hepatic fibrosis,and the nor-mal control group were administrated with same volume of 0.9% saline(n = 6). the experimental mice then were randomly divided into four treat-ment groups and treated for six weeks:saline therapy group(0.9% saline,100 μL/mouse,n = 6),IFN-α therapy group(IFN-α 800 U/mouse,n =6),1,25-(OH)2D3 therapy group(50 μg/kg,by gavaged,n = 6)and combined treatment therapy group(combined treatment,n=6). Hepatic inju-ry and hepatic pathology were examined by HE staining and Masson staining. Interleukin-6(IL-6),interleukin-10(IL-10),tumor necrosis factor-α(tNF-α),transforming growth factor-β(tGF-β)and Smad3 were determined by real-time PCR and ELISA. Results Inflammatory cell infiltra-tion and periportal collagen deposition were significantly reduced in all the therapeutic group expect saline therapy group assessed by HE and Masson staining. the IFN-α therapy group,1,25-(OH)2D3 therapy group and combined treatment therapy group displayed significant decrease in Col1α1, IL-6,tNF-α,tGF-β and Smad3 expression and increase in IL-10 expression in liver tissue(P < 0.05). Conclusion the effect of 1,25-(OH)2D3 combined with IFN-α therapy is similar to separated treatment.

0.05).Conclusion: The therapeutic effect of combination of western medicine and diarrhea method of TCM for treatment of SAP is superior to that of the western medicine alone, it can relieve the abdominal pain and distension rapidly and efficiently,and no gastrointestinal decompression is necessary when the combination method is adopted.The recovery of defecation and rugitus may be the important clinical signs of SAP improvement.

Objective:To investigate the thyroid function status and levothyroxine ( L-T 4) replacement therapy strategy in pregnant women after 131I treatment of hyperthyroidism. Methods:From January 2005 to December 2019, 88 patients (age: (27.3±3.7) years) who received 131I treatment in Nanjing Drum Tower Hospital were retrospectively analyzed. They became pregnant at least half a year after 131I treatment with normal thyroid function and delivered successfully. Thyroid stimulating hormone (TSH), free triiodothyronine (FT 3) and free thyroxine (FT 4) were respectively detected at 1-3 months before pregnancy, 4-7, 8-12, 13-22, 23-28, ≥29 weeks of pregnancy, and 6 weeks, 3 months, 6 months of postpartum. According to the 2011 American Thyroid Association guidelines, L-T 4 replacement therapy was performed to maintain normal thyroid function. Repeated measures analysis of variance and the least significant difference t test were used to analyze data. Results:There were significant differences in TSH, FT 3, FT 4 and L-T 4 among different time periods before pregnancy, pregnancy and postpartum ( F values: 5.94, 3.32, 3.49, 9.63, all P<0.05). In order to maintain normal thyroid function in each period of pregnancy, the doses of L-T 4 replacement therapy were increased to (82.33±35.06) μg and (100.75±36.77) μg at 4-7, 8-12 weeks of pregnancy compared with the dose ((64.52±34.32) μg) before pregnancy ( t values: 7.33, 10.44, both P<0.001). The doses of L-T 4 were increased slowly after 13 weeks of pregnancy. In the third trimester (≥29 weeks), the dose was 76.69% higher than that before pregnancy. There were significant changes of TSH, FT 3 and FT 4 at 6 weeks of postpartum compared with those in the third trimester (TSH: (1.21±1.08) vs (2.99±1.42) mU/L, FT 3: (5.23±1.07) vs (3.90±0.55) pmol/L, FT 4: (21.29±4.96) vs (15.37±2.29) pmol/L, t values: -2.48, 6.05, 5.88, P values: 0.017, <0.001, <0.001). Compared with that in the third trimester, the dose of L-T 4 was decreased significantly at 6 weeks of postpartum ( t=-6.85, P<0.001), but doses of L-T 4 at 6 weeks, 3 months and 6 months of postpartum were still higher than that before pregnancy ( t values: 4.67-4.71, all P<0.001). Conclusions:TSH, FT 3 and FT 4 should be regularly monitored at 1-3 months before pregnancy, gestation period and 6 weeks of postpartum in pregnant women after 131I treatment of hyperthyroidism. The dose of L-T 4 should be adjust to the serum TSH level as soon as possible.